Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | terminated | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | terminated | Phase 3 | 16 | GlaxoSmithKlineINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | terminated | Phase 1 | 6 | Vincerx Pharma, Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | terminated | Phase 1 / Phase 2 | 3 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 72 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | terminated | Phase 1 | 98 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | terminated | Phase 2 | 19 | OncotherapeuticsINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients(ClaSPd) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma(LOTIS-6) | terminated | Phase 2 | 6 | ADC Therapeutics S.A.INDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 17 | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04805203 | Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma(Covimmunomm) | terminated | N/A | 139 | Intergroupe Francophone du MyelomeNETWORK | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 1 / Phase 2 | 6 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | terminated | Phase 1 / Phase 2 | 32 | Sherif Farag, MB, BSOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma(DYNAMO + R) | terminated | Phase 3 | 13 | SecuraBioINDUSTRY | 4 | Sep 28, 2023 | clinicaltrials |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | terminated | Phase 1 / Phase 2 | 55 | SecuraBioINDUSTRY | 6 | Sep 28, 2023 | clinicaltrials |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Srinivas DevarakondaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)(CHOP U2) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04142619 | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | terminated | Phase 1 | 11 | Cellectis S.A.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04171843 | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 48 | Precision BioSciences, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | terminated | Phase 1 | 2 | Virtuoso BINco, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | terminated | Phase 2 | 12 | Hackensack Meridian HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | terminated | Phase 2 | 2 | Andrew Yee, MDOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse(OPERA-PLRG10) | terminated | Phase 2 | 1 | Polish Lymphoma Research GroupNETWORK | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | terminated | Phase 3 | 96 | Gilead SciencesINDUSTRY | 10 | Aug 14, 2023 | clinicaltrials |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | terminated | Phase 1 | 9 | AstraZenecaINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02134782 | Yoga Fatigue Study | terminated | N/A | 125 | The Hospital for Sick ChildrenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | terminated | Phase 2 | 34 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | terminated | Phase 2 | 41 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | terminated | Phase 1 | 12 | University of WashingtonOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | terminated | Phase 2 | 31 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | terminated | Early Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | terminated | Phase 2 | 116 | TG Therapeutics, Inc.INDUSTRY | 4 | Jun 22, 2023 | clinicaltrials |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma(LIGHTHOUSE) | terminated | Phase 3 | 54 | Oncopeptides ABINDUSTRY | 11 | Jun 8, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | terminated | Phase 3 | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2024source: clinicaltrials